Companies

On October 1st 2011 TAKEDA bought NYCOMED, the previous parent company of LEIRAS. Nowadays LEIRAS and its three NYCOMED sister companies in Scandinavia are fully integrated part of the global pharma company TAKEDA. At TAKEDA Nordic, we are applying Cluster Concept, meaning that certain functions are shared between different affiliates acting in same region. Business Development is one of those co-ordinated functions. 

We are looking for new chemical substances and new value added prescription products for the region covering all Nordic markets. Our general requirements for new prescription drugs are: 1) developed at least up to phase III, or NDA ready, or submitted or even Marketing Authorization granted 2) product does not require TAKEDAs participation / commitment on new clinical trials 3) drug serves unmet medical need 4) drug has patent coverage available for number of years ahead 5) drug is directed mainly to specialist.

Our therapeutic focus for Nordic countries lies on 1) respiratory diseases 2) pain management 3) oncology 4) cardiovascular health and 5) metabolic diseases.

This Nordic region represents a remarkable market segment in European market. However even pure single market opportunities will be fully evaluated.TAKEDA has strong market position in all Nordic markets, through it´s bought NYCOMED affilaites, covering both primary and hospital care prescription drugs, and having strong OTC presence as well.  We have strong sales forces in all Nordic countries and appropriate marketing function providing support for the sales force. TAKEDAs own global R&D and corporate licensing provide together the back bone  of new products pipeline. Our regional in-licensing is represents a very important role in our regional portfolio development and alliance management.

TAKEDA in Nordicsis  ready to make quick and full medical and market assesment for regional in-licensing product opportunities. Please make your contact to Mr Raimo Skottman  ( raimo.skottman@leiras.fi ) 

Further info about TAKEDA (www.takeda.com) or (www.nycomed.com ) or (www.leiras.fi/english )

We are looking for new prescription bound chemical substances (NCEs) OR new value added prescription products to be in-licensed for the region covering all four Nordic markets (Finland / Sweden / Norway and Denmark) .

Our general requirements for new prescription drugs are:
1) product is developed at least up to phase III, or NDA ready, or NDA has been submitted
    or even Marketing Authorization granted 
2) new drug does not require TAKEDAs participation / commitment on new clinical trials
3) new drug serves unmet medical need
4) new drug has patent coverage available for number of years ahead
5) drug is directed mainly to specialist.
6) products are delivered in final packages and relased in EU by supplier 

Our therapeutic areas focus for Nordic countries lies on 1) respiratory diseases 2) pain management 3) oncology diseases 4) cardiovascular health and 5) metabolic diseases.

Moreover we look for complementary products around following anchor brands in our portfolio: DAXAS(roflumilast) for COPD, TACHOSIL(medicated sponge) for stopping bleeding, DIFORMIN(metformin) for type II diabetes, LEVAXIN(levothyroxin) for hypothyroidism

Oy Leiras Finland provides prescription drugs for diabetes and hypertension, migraine, allergy and osteoporosis as well as hospital and base care products. It also offers self-care preparation for women's health, pain, the common cold and base care products. In co-operation with different doctors' associations, the Leiras EduCenter® offers expert and versatile postgraduate and further education. The company's product areas include: cardiovascular diseases, arthrosis and osteoporosis, specialty products for hospital care, self-care products and base care products.

Cardiovascular diseases and specialty products for hospital care include, DIFORMIN®, a type 2 antidiabetic agent (metformin); OLMETEC®, an AT1 receptor blocker (olmesartan); SPESICOR® DOS, metoprolol succinate; ZANIDIP®, anti-hypertension drug (lercanidipine); ANGIOX(TM), thrombin inhibitor (bivalirudin) and TACHOSIL®, medicated sponge containing fibrinogen and thrombin.

Partnership is essential to the company's business. The company's vision is to be the preferred partner in Finland. All that we do, whether in our relationships with healthcare providers such as specialists, general practitioners and pharmacists, or its partners in product development, is done with that end in sight.

The company relies on its partners' research skills and they in turn rely on its product development and local understanding. Leiras also builds partnerships to export or out-license our products to other pharmaceutical companies, primarily in areas where we don't maintain our own sales force. Equally crucial is the partnership with the medical community and our customers. Listening to their concerns and acting upon their ideas helps us identify new products for development that are of potentially high value in the Finnish market.